Log In
Print
BCIQ
Print
Print this Print this
 

nesvacumab (REGN910, SAR307746)

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
Description mAb against angiopoietin 2 (ANG2; ANGPT2)
Molecular Target Angiopoietin 2 (ANG2) (ANGPT2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$65.0M

$20.0M

$45.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today